Patents by Inventor Graeme Richard Robb

Graeme Richard Robb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SPIROCYCLIC COMPOUNDS
    Publication number: 20230357279
    Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: June 15, 2023
    Publication date: November 9, 2023
    Inventors: JAMES MICHAEL SMITH, GRAEME RICHARD ROBB, PIOTR ANTONI RAUBO, BERNARD CHRISTOPHE BARLAAM, IAIN ALEXANDER CUMMING
  • Tetracyclic heteroaryl compounds
    Patent number: 11407765
    Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: August 9, 2022
    Assignee: AstraZeneca, AB
    Inventors: Jason Grant Kettle, Sharanjeet Kaur Bagal, Andrew John Eatherton, Shaun Michael Fillery, Graeme Richard Robb, Scott Gibson Lamont, Paul David Kemmitt, Frederick Woolf Goldberg
  • HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS
    Publication number: 20220127281
    Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: October 5, 2021
    Publication date: April 28, 2022
    Inventors: Jason Grant KETTLE, Sharanjeet Kaur BAGAL, Scott BOYD, Andrew John EATHERTON, Shaun Michael FILLERY, Graeme Richard ROBB, Piotr Antoni RAUBO
  • TETRACYCLIC HETEROARYL COMPOUNDS
    Publication number: 20210221823
    Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: May 7, 2019
    Publication date: July 22, 2021
    Inventors: Jason Grant KETTLE, Sharanjeet Kaur BAGAL, Andrew John EATHERTON, Shaun Michael FILLERY, Graeme Richard ROBB, Scott Gibson LAMONT, Paul David KEMMITT, Frederick Woolf GOLDBERG
  • HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS
    Publication number: 20200109153
    Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: May 8, 2018
    Publication date: April 9, 2020
    Inventors: Jason Grant KETTLE, Sharanjeet Kaur BAGAL, Scott BOYD, Andrew John EATHERTON, Shaun Michael FILLERY, Graeme Richard ROBB, Piotr Antoni RAUBO
  • Chemical compounds
    Patent number: 10597405
    Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: March 24, 2020
    Assignee: AstraZeneca AB
    Inventors: Jason Grant Kettle, Sharanjeet Bagal, Graeme Richard Robb, James Michael Smith, Frederick Woolf Goldberg, Doyle Joseph Cassar, James Lyman Feron
  • CHEMICAL COMPOUNDS
    Publication number: 20190177338
    Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 13, 2019
    Inventors: Jason Grant Kettle, Sharanjeet Bagal, Graeme Richard Robb, James Michael Smith, Frederick Woolf Goldberg, Doyle Joseph Cassar, James Lyman Feron
  • THERAPEUTIC AGENTS
    Publication number: 20120115845
    Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1, R2, R3, R4 and m are as described in the specification for use in the treatment of obesity and/or diabetes.
    Type: Application
    Filed: November 7, 2011
    Publication date: May 10, 2012
    Inventors: Jack McQueen ALLEN, Roger John Butlin, Clive Green, William McCoull, Graeme Richard Robb, James Matthew Wood
  • Therapeutic agents
    Patent number: 8143263
    Abstract: A compound of Formula (I): is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: March 27, 2012
    Assignee: Astrazeneca AB
    Inventors: Stuart Norman Lile Bennett, Roger John Butlin, Leonie Campbell, Robert Darren Morse Davies, Graeme Richard Robb, Rolf Peter Walker, Michael James Waring, Helen Claire Pointon, Mikael Dan Brink, Jonas Rickard Fägerhag, Ulrik Jurva, Volker Schnecke, Anette Marie Svensson Henriksson, Christer Ralf Westerlund, Peter Gustaf Bonn
  • BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS
    Publication number: 20110124621
    Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1, R2, R3, R4 and m are as described in the specification for use in the treatment of obesity and/or diabetes.
    Type: Application
    Filed: October 8, 2008
    Publication date: May 26, 2011
    Inventors: Jack McQueen Allen, Roger John Butlin, Clive Green, William Mccoull, Graeme Richard Robb, James Matthew Wood
  • THERAPEUTIC AGENTS 414
    Publication number: 20100093757
    Abstract: A compound of Formula (I): is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.
    Type: Application
    Filed: August 4, 2009
    Publication date: April 15, 2010
    Applicant: AstraZeneca AB
    Inventors: Stuart Norman Lile BENNETT, Roger John Butlin, Leonie Campbell, Robert Darren Morse Davies, Graeme Richard Robb, Rolf Peter Walker, Michael James Waring, Helen Claire Pointon, Mikael Dan Brink, Jonas Rickard Fägerhag, Ulrik Jurva, Volker Schnecke, Anette Marie Svensson Henriksson, Christer Ralf Westerlund, Peter Gustaf Bonn
  • Therapeutic Agents - 802
    Publication number: 20090186870
    Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1, R2, R3, R4 and m are as described in the specification for use in the treatment of obesity and/or diabetes.
    Type: Application
    Filed: October 9, 2008
    Publication date: July 23, 2009
    Applicant: AstraZeneca AB
    Inventors: Jack McQueen ALLEN, Roger John Butlin, Clive Green, William McCoull, Graeme Richard Robb, James Matthew Wood
  • HETEROBICYCLIC COMPOUNDS AS GLUCOKINASE ACTIVATORS
    Publication number: 20090105263
    Abstract: Compounds of Formula (I): wherein R1 to R11, A and X1 to X3 are as described in the specification, and their salts, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of Formula (I) are also described.
    Type: Application
    Filed: September 12, 2006
    Publication date: April 23, 2009
    Inventors: Peter William Rodney Caulkett, Darren McKerrecher, Nicholas John Newcombe, Kurt Gordon Pike, Graeme Richard Robb, Michael James Waring